$890,000.00 in Sales Expected for Spero Therapeutics Inc (SPRO) This Quarter
Analysts forecast that Spero Therapeutics Inc (NASDAQ:SPRO) will post $890,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Spero Therapeutics’ earnings, with the highest sales estimate coming in at $1.28 million and the lowest estimate coming in at $400,000.00. Spero Therapeutics posted sales of $990,000.00 during the same quarter last year, which suggests a negative year-over-year growth rate of 10.1%. The company is scheduled to announce its next earnings results on Monday, April 1st.
According to Zacks, analysts expect that Spero Therapeutics will report full-year sales of $3.20 million for the current financial year, with estimates ranging from $2.67 million to $3.55 million. For the next year, analysts expect that the firm will post sales of $11.80 million, with estimates ranging from $7.50 million to $18.60 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings results on Thursday, November 8th. The company reported ($0.60) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.64) by $0.04. Spero Therapeutics had a negative net margin of 1,402.91% and a negative return on equity of 52.22%. The firm had revenue of $0.66 million for the quarter, compared to the consensus estimate of $0.66 million.
Several large investors have recently modified their holdings of the company. Point72 Asset Management L.P. acquired a new stake in shares of Spero Therapeutics in the 3rd quarter valued at $462,000. EcoR1 Capital LLC acquired a new stake in shares of Spero Therapeutics in the 3rd quarter valued at $9,383,000. Aquilo Capital Management LLC boosted its stake in shares of Spero Therapeutics by 91.9% in the 3rd quarter. Aquilo Capital Management LLC now owns 799,691 shares of the company’s stock valued at $8,405,000 after purchasing an additional 383,000 shares in the last quarter. Highland Capital Management LP acquired a new stake in shares of Spero Therapeutics in the 3rd quarter valued at $210,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Spero Therapeutics in the 3rd quarter valued at $126,000. Institutional investors own 43.58% of the company’s stock.
SPRO traded down $0.02 during trading on Thursday, reaching $7.77. 139,593 shares of the company’s stock were exchanged, compared to its average volume of 82,263. Spero Therapeutics has a fifty-two week low of $7.18 and a fifty-two week high of $19.00. The company has a market capitalization of $140.95 million and a P/E ratio of -0.44.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.
Featured Article: Do closed-end mutual funds pay dividends?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.